Clinical Trials Logo

Clinical Trial Summary

This interventional study aims to determine the pharmacokinetics of orally administered alectinib with dose escalation from 300 mg to 600 mg twice daily in Mexican patients with advanced ALK-positive NSCLC. The main question it aims to answer is: what will be the peak plasma concentrations of alectinib following sequential dose escalation (300, 450, and 600 mg BID) over nine weeks of pharmacokinetic evaluation (phase I) in Mexican patients with advanced ALK-rearranged NSCLC? In phase I (on days 0, 21, and 42), oral alectinib will be administered twice per day (BID) to patients with ALK-positive NSCLC; starting with 300 mg BID in 21-day cycles and dose escalation in 150 mg increments until 600 mg BID. Blood samples will be taken before and after administration of each dose (on days 1, 22, and 43). The primary endopoints in phase I will be dose-limiting toxicity (DLT) and PK parameters (Cmax. maximum plasma concentration; Tmax: time to reach maximum concentration: AUC 1-12: area under plasma ocncentrations-time curve steady-state concentration). At the end of the last blood collection (at day 43), the evaluation of each cycle will be at 600 mg, and the participant will be discharged to continue their treatment on an outpatient basis. Phase one will finish on day 63 of the study. In phase II, the chosen BID dose based on the phase I portion will be administrated until disease progression, development of unacceptable side effects, or withdrawal of consent. The primary endpoint in phase 2 is the overall response rate (ORR) per RECIST V.1.1.


Clinical Trial Description

Alectinib will be administrated under fast conditions. The primary endpoint of the phase II part was ORR. Other secondary endpoints in phase II are progression-free survival (PFS), overall survival (OS), intracranial response (ICR), and duration of response (DOR). Exploratory endpoints in this follow-up analysis included the evaluation of the correlation between tumor shrinkage and PFS and chosen dose to relieve cancer symptoms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05713006
Study type Interventional
Source Instituto Nacional de Cancerologia de Mexico
Contact Oscar G Arrieta Rodriguez, M.D., M.Sc.
Phone 5556280400
Email ogar@unam.mx
Status Recruiting
Phase Phase 1/Phase 2
Start date May 1, 2022
Completion date December 1, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02035683 - PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy N/A
Terminated NCT00766246 - Phase II Avastin Trial for Stage IIIB/IV NSCLC Phase 2
Terminated NCT03386929 - Survival Prolongation by Rationale Innovative Genomics Phase 1/Phase 2
Recruiting NCT01493011 - Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer N/A
Not yet recruiting NCT06394427 - Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
Terminated NCT01348126 - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Phase 2/Phase 3
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT01798485 - A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Phase 3
Active, not recruiting NCT01405586 - MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer Phase 3
Withdrawn NCT03628144 - Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer Phase 2
Completed NCT02176369 - Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial Phase 2
Active, not recruiting NCT03611738 - Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Phase 1
Completed NCT01473563 - A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Phase 2
Active, not recruiting NCT01656551 - MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer Phase 3
Not yet recruiting NCT03532698 - Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
Not yet recruiting NCT03543683 - Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC